Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview

Mantle, D and Hargreaves, IP (2019) Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview. Antioxidants, 8 (2). ISSN 2076-3921

[img]
Preview
Text
antioxidants-29.3.19.pdf - Published Version
Available under License Creative Commons Attribution.

Download (374kB) | Preview

Abstract

Longevity is determined by a number of factors, including genetic, environmental and lifestyle factors. A major factor affecting longevity is the development of degenerative disorders such as cardiovascular disease, diabetes, kidney disease and liver disease, particularly where these occur as co-morbidities. In this article, we review the potential role of supplementation with coenzyme Q10 (CoQ10) for the prevention or management of these disorders. Thus, randomised controlled clinical trials have shown supplementation with CoQ10 or CoQ10 plus selenium reduces mortality by approximately 50% in patients with cardiovascular disease, or in the normal elderly population, respectively. Similarly, CoQ10 supplementation improves glycaemic control and vascular dysfunction in type II diabetes, improves renal function in patients with chronic kidney disease, and reduces liver inflammation in patients with non-alcoholic fatty liver disease. The beneficial role of supplemental CoQ10 in the above disorders is considered to result from a combination of its roles in cellular energy generation, as an antioxidant and as an anti-inflammatory agent.

Item Type: Article
Uncontrolled Keywords: Science & Technology; Life Sciences & Biomedicine; Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science & Technology; Pharmacology & Pharmacy; coenzyme Q10; oxidative stress; inflammation; diabetes; cardiovascular disease; chronic kidney disease and liver disease; mitochondria; FATTY LIVER-DISEASE; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; SERUM COENZYME-Q10; OXIDATIVE STRESS; STATIN TREATMENT; UREMIC PATIENTS; INCREASED RISK; SUPPLEMENTATION; Q(10)
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: MDPI AG
Related URLs:
Date Deposited: 02 Apr 2019 09:02
Last Modified: 02 Apr 2019 09:08
DOI or Identification number: 10.3390/antiox8020044
URI: http://researchonline.ljmu.ac.uk/id/eprint/10462

Actions (login required)

View Item View Item